Health
SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated – News-Medical.Net
However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a val…
Eight months into the COVID-19 pandemic, there is still no fully protective therapy against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has infected millions worldwide. Vaccines are being worked on in a host of institutions and countries, mostly targeting the spike protein of the virus. However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint s…
-
Business19 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Noosa News18 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane
-
Business18 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News21 hours agoEverything To Know About Spilt Milk 2025